\-\ Texto\\:\\ \ \(0\)\
\-\ upper\\ extremity\\ weakness\\.\ \(6\)\
\-\ elevated\\ oligoclonal\\ bands\\ in\\ csf\\.\ \(0\)\
\-\ steroids\\ and\\ various\\ other\\ medications\ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ supratentorial\\ foci\\ of\\ elevated\\ t2\\ signal\\ both\\ adjacent\\ to\\ ventricle\\ and\\ in\\ the\\ peripheral\\ white\\ matter\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enhancement\\ of\\ right\\ parietal\\ lesion\ \(0\)\
\-\ \\â\\€\\¢\\ cerebral\\ atrophy\ \(0\)\
\-\ \\â\\€\\¢\\ abnormal\\ signal\\ in\\ cervical\\ cord\\ with\\ enhancement\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ pml\ \(0\)\
\-\ adem\ \(8\)\
\-\ sspe\ \(0\)\
\-\ transverse\\ myelitis\ \(14\)\
\-\ 42\\ year\\ old\\ woman\\ with\\ long\\ history\\ of\\ multiple\\ sclerosis\ \(0\)\
\-\ the\\ enhancing\\ plaques\\ in\\ the\\ cervical\\ spinal\\ cord\\ and\\ right\\ occipital\\ region\\ indicate\\ areas\\ of\\ acute\\ \\(active\\)\\ plaque\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sclerosis\\:\\ 0\\.2983897604247315\ \(0\)\
\-\ multiple\\:\\ 0\\.27320583430853584\ \(0\)\
\-\ sspe\\:\\ 0\\.2233163796249034\ \(0\)\
\-\ cord\\:\\ 0\\.20702066387421728\ \(0\)\
\-\ cervical\\:\\ 0\\.2000267636780819\ \(0\)\
\-\ pml\\:\\ 0\\.19264914057711577\ \(0\)\
\-\ elevated\\:\\ 0\\.19039027601575645\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.18158468849443635\ \(0\)\
\-\ myelitis\\:\\ 0\\.16820547238192285\ \(0\)\
\-\ enhancement\\:\\ 0\\.1607498723806557\ \(0\)\
\-\ supratentorial\\:\\ 0\\.15871309550537724\ \(0\)\
\-\ signal\\:\\ 0\\.15831704013440764\ \(0\)\
\-\ adem\\:\\ 0\\.14998180631244817\ \(0\)\
\-\ bands\\:\\ 0\\.14821141951739442\ \(0\)\
\-\ plaque\\:\\ 0\\.14656047841212722\ \(0\)\
\-\ indicate\\:\\ 0\\.14218616025371963\ \(0\)\
\-\ plaques\\:\\ 0\\.1408860486207542\ \(0\)\
\-\ various\\:\\ 0\\.13965151736268439\ \(0\)\
\-\ in\\:\\ 0\\.13895260837416168\ \(0\)\
\-\ atrophy\\:\\ 0\\.13211258942262294\ \(0\)\
\-\ 42\\:\\ 0\\.12412997270727974\ \(0\)\
\-\ steroids\\:\\ 0\\.12268349482681513\ \(0\)\
\-\ occipital\\:\\ 0\\.11949004960727494\ \(0\)\
\-\ medications\\:\\ 0\\.11714088169442019\ \(0\)\
\-\ foci\\:\\ 0\\.11413346284842303\ \(0\)\
\-\ parietal\\:\\ 0\\.11275783793194012\ \(0\)\
\-\ csf\\:\\ 0\\.11033969713698752\ \(0\)\
\-\ of\\:\\ 0\\.10930851260571578\ \(0\)\
\-\ transverse\\:\\ 0\\.10759142929198112\ \(0\)\
\-\ matter\\:\\ 0\\.10632495643638258\ \(0\)\
\-\ active\\:\\ 0\\.1036943905633611\ \(0\)\
\-\ ventricle\\:\\ 0\\.1027876320130029\ \(0\)\
\-\ weakness\\:\\ 0\\.10191326471046187\ \(0\)\
\-\ extremity\\:\\ 0\\.10057615793373752\ \(0\)\
\-\ peripheral\\:\\ 0\\.09985493674242188\ \(0\)\
\-\ spinal\\:\\ 0\\.09915435749028718\ \(0\)\
\-\ cerebral\\:\\ 0\\.09674457581509008\ \(0\)\
\-\ areas\\:\\ 0\\.09480656346879393\ \(0\)\
\-\ long\\:\\ 0\\.09259637017653068\ \(0\)\
\-\ right\\:\\ 0\\.09259354710543038\ \(0\)\
\-\ white\\:\\ 0\\.09213118407447528\ \(0\)\
\-\ adjacent\\:\\ 0\\.09051532851447774\ \(0\)\
\-\ enhancing\\:\\ 0\\.08747676186047355\ \(0\)\
\-\ and\\:\\ 0\\.08656531711495752\ \(0\)\
\-\ abnormal\\:\\ 0\\.0838944507315351\ \(0\)\
\-\ the\\:\\ 0\\.08359032578116894\ \(0\)\
\-\ region\\:\\ 0\\.08352694234842342\ \(0\)\
\-\ t2\\:\\ 0\\.08033932937391741\ \(0\)\
\-\ both\\:\\ 0\\.0778706875980384\ \(0\)\
\-\ acute\\:\\ 0\\.07554044922677505\ \(0\)\
\-\ upper\\:\\ 0\\.07462199469818853\ \(0\)\
\-\ woman\\:\\ 0\\.0727254961124949\ \(0\)\
\-\ other\\:\\ 0\\.07251781994039405\ \(0\)\
\-\ lesion\\:\\ 0\\.06694700800517235\ \(0\)\
\-\ with\\:\\ 0\\.05468691220797546\ \(0\)\
\-\ history\\:\\ 0\\.05335095086195606\ \(0\)\
\-\ year\\:\\ 0\\.04303461089086568\ \(0\)\
\-\ old\\:\\ 0\\.04132812325547849\ \(0\)\
\-\ to\\:\\ 0\\.03490997893757009\ \(0\)\
